Previously unreported biological activity of endocrine disrupting chemicals (EDCs) has been detected in water samples from 14 states in the US by researchers at the National Cancer Institute, Maryland, USA.1
Previously unreported biological activity of endocrine disrupting chemicals (EDCs) has been detected in water samples from 14 states in the US by researchers at the National Cancer Institute, Maryland, USA.1 The findings demonstrate the presence of androgen and glucocorticoid in US water sources.
The reporting of EDCs in water sources is not new: The New York Times ran several articles on the issue in 2009.2 Researchers previously focused on the identification of contaminants but this new study concentrates on creating an assay for biological activity. This suggests that although levels of androgen and glucocorticoid have previously been undetected, there are biologically relevant concentrations of these chemicals present.
EDCs are chemicals that alter the functioning of an organism by interfering with the endocrine (hormone) system. This can affect aquatic ecosystems as well as human health. Estrogenic compound contamination has been associated with reproduction issues, cancer occurrence, obesity and thyroid metabolism.2 The origin of ECDs in water sources has been attributed to pharmaceutical waste disposal and increased use of prescription drugs by the general population. Anti-inflammatory drugs, classed as glucocorticoids, have a low recovery rate by water treatment plants and can enter water sources in the environment.
Dr Hager, co-author of the study, told The Column that currrent analysis and screening methods are: “expensive and not applicable for large‑scale screening” with approaches focusing on the identification of specific compounds rather than activity. The use of traditional chromatographic methods and analysis can identity known chemicals within samples, but not necessarily unknown or chemicals present at low concentrations. To fill this gap in analysis, the scientists designed a living cell‑based system that could be used to process a high throughput of samples.
Androgen and glucocorticoid have a similar method of changing cell behaviour. The hormones are taken up inside the cell where they bind to their partner receptors. Once partnered, the hormones are transported to the DNA of the cell, where they alter the expression of other hormones and proteins. The scientists exploited this capability to create a reporter system. In the presence of ECDs expression of green fluorescent protein (GFP) is activated. GFP is a commonly used reporter derived from the jellyfish Aequorea victoria, which on exposure to light glows a distinctive green colour. Therefore, when the cell system was exposed to androgen or glucocorticoid, the cells glowed green.
Water samples were prepared for analysis by fractionation using high performance liquid chromatography (HPLC); subsequently, each fraction was tested using the cell-based assay. Glucocorticoid activity was found in 27% of water source samples collected from 14 US states; and androgen activity was found in 35% of the samples. Environmental degradation and metabolic processes are thought to alter the structure of known ECDs producing new bioactive structures that are not contained on any databases. This poses a potential health hazard according to the authors of the study.1
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.